Effects of Moderate Weight Loss and Orlistat on Insulin Resistance, Regional Adiposity, and Fatty Acids in Type 2 Diabetes

Diabetes Care

Volumn 27, Issue 1, 2004, Pages 33-40

  Kelley, David E ^a   Kuller, Lewis H ^b   McKolanis, Therese M ^a   Harper, Patricia ^a   Mancino, Juliet ^a   Kalhan, Satish ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; HEMOGLOBIN A1C; PLACEBO; TETRAHYDROLIPSTATIN;

ADIPOSE TISSUE; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FATTY LIVER; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; VISCERA; WEIGHT REDUCTION;

ADIPOSE TISSUE; BLOOD GLUCOSE; BODY COMPOSITION; BODY MASS INDEX; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LACTONES; OBESITY; PLACEBOS; TIME FACTORS; WEIGHT LOSS;

EID: 1042291848     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.1.33     Document Type: Article

References (41)

1. Hu F, Manson J, Stampfer M, Colditz G, Liu S, Solomon C, Willett W: Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 345:790-797, 2001
2. Pi-Sunyer FX: Medical hazards of obesity. Ann Intern Med 119:655-660, 1993
3. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP: The continuing epidemics of obesity and diabetes in the United States. JAMA 286:1195-1200, 2001
4. Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, Barakat HA, deRamon RA, Israel G, Dolezal JM: Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222:339-352, 1995
5. Sjostrom CD, Peltonen M, Wedel H, Sjostrom L: Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 36:20-25, 2000
6. Goldstein D: Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 16:397-415, 1992
7. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D: Long-term effects of modest weight loss in type 11 diabetic patients. Arch Intern Med 147:1749-1753, 1987
8. American Diabetes Association: Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications (Position Statement). Diabetes Care 25 (Suppl. 1):S50-S60, 2002
9. National Institutes of Health: Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults - the evidence report. Obesity Res 6:51S-209S, 1998
10. Phelan S, Wadden T: Combining behavioral and pharmacological treatments for obesity. Obesity Res 10:560-574, 2002
11. Yanovski S, Yanovski J: Drug therapy: obesity. N Engl J Med 346:591-602, 2002
12. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J: Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blinded study. Diabetes Care 21:1288-1294, 1998
13. Kelley D, Bray G, Pi-Sunyer F, Klein S, Hill J, Miles J, Hollander P: Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 25:1033-1042, 2002
14. Miles J, Leiter L, Hollander PA, Wadden T, Anderson J, Doyle M, Foreyt JP, Aronne L, Klein S: Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 25:1123-1128, 2002
15. Heymsfield SB, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, Wilding JPH, Sjostrom L: Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 160:1321-1326, 2000
16. Ballinger A: Orlistat in the treatment of obesity. Exp Opin Pharmacother 1:841-847, 2000
17. Bray G, Greenway FL: Current and potential drugs for treatment of obesity. Endocr Rev 20:805-875, 1999
18. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH: Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. Lancet 1:1356-1359, 1989
19. UK Prospective Diabetes Study: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 128:165-175, 1998
20. Kelley DE, McKolanis T, Hegazi R, Kuller L, Kalhan S: Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol (Endocrinol Metab) 285:E906-E916, 2003
21. Frayn K: Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 55:628-634, 1983
22. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979
23. Kelley D, Troost F, Huwe T, Thaete F, Goodpaster B: Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance. Am J Physiol 278:E941-E948, 2000
24. Longo R, Ricci C, Masutti F, Vidimari R, Croce LS, Bercich L, Tiribelli C, Dalla Palma L: Fatty infiltration of the liver quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography. Invest Radiol 28:297-302, 1993
25. Wolfe R: Radioactive and Stable Isotope Tracers in Biomedicine. New York, Wiley-Liss, 1992, p. 119-144
26. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 352:167-173, 1998
27. Lemieux S, Prud'homme D, Bouchard C, Tremblay A, Despres J-P: Sex differences in the relation of visceral adipose tissue accumulation to total body fatness. Am J Clin Nutr 58:463-467, 1993
28. Goodpaster BH, Kelley DE, Thaete FL, He J, Ross R: Skeletal muscle attenutation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol 89:104-110, 2000
29. Leibel, L, Rosenbaum M, Hirsch J: Changes in energy expenditure resulting from altered body weight. N Engl J Med 332:621-628, 1995
30. Nathan D: Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 347:1342-1349, 2002
31. Watts N, Spanheimer R, Girolamo M, Gebhart S, Musey V, Siddiq Y, Phillips L: Prediction of glucose response to weight loss in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 150:803-806, 1990
32. Kelley DE, Wing R, Buonocore C, Sturis J, Polonsky K, Fitzsimmons M: Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 77:1287-1293, 1993
33. Wing RR, Blair EH, Bononi P, Marcus MD, Watanabe R, Bergman RN: Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care 17:30-36, 1994
34. Christiansen MP, Linfoot PA, Neese RA, Hellerstein MK: Effect of dietary energy restriction on glucose production and substrate utilization in type 2 diabetes. Diabetes 49:1691-1699, 2000
35. Kelley D, Williams K, Price J, McKolanis T, Goodpaster B, Thaete F: Plasma fatty acids, adiposity and variance of skeletal muscle insulin resistance in type 2 diabetes meliitus. J Clin Endocrinol Metab 86:5412-5419, 2001
36. Piatti PM, Monti LD, Davis SN, Conti M, Brown MD, Pozza G, Alberti KG: Effects of an acute decrease in non-esterified fatty acid levels on muscle glucose utilization and forearm indirect calorimetry in lean NIDDM subjects. Diabetologia 1996:103-112, 1996
37. Santomauro AT, Boden G, Silva ME, Rocha DM, Santos RF, Ursich MJ, Strassmann PG, Wajchenberg BL: Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 48:1836-1841, 1999
38. Tan K, Tso A, Tam S, Pang R, Lam K: Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with type 2 diabetes mellitus. Diabet Med 19:944-948, 2002
39. Kelley D, Jneidi M: Orlistat in the treatment of type 2 diabetes mellitus. Exp Opin Pharmacother 3:599-605, 2002
40. Ricci C, Gioulis E, Bosco M, Pollesello P, Masutti F, Croce L, Paoletti S, Bernard B, Tiribelli C, Dalla Palma L: Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol 27:108-113, 1997
41. Ryysy L, Takashi G, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Jarvinen H: Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49:749-758, 2000